Robenidine hydrochloride, drug combination thereof and application in treatment of babesiasis

A technology of prohexidine hydrochloride and combined medication, which is applied in the field of medicine, can solve the problems of easy recurrence, treatment failure, side effects, etc., and achieve good and excellent therapeutic effects

Pending Publication Date: 2022-02-18
中国疾病预防控制中心寄生虫病预防控制所国家热带病研究中心
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to literature reports, the course of clinical medication for babesiosis generally needs to be 10-15 days, and long-term medication of these regimens has certain side effects
Moreover, there are common reports of poor treatment effect and easy relapse, and there are failure cases in the treatment of patients with immune insufficiency, so it is urgent to find new effective clinical treatment drugs or programs
The drug treatment regimen used is not effective, especially for the common failure of treatment in severe cases, some patients relapse after being clinically "cured" under the condition of low immunity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Robenidine hydrochloride, drug combination thereof and application in treatment of babesiasis
  • Robenidine hydrochloride, drug combination thereof and application in treatment of babesiasis
  • Robenidine hydrochloride, drug combination thereof and application in treatment of babesiasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] The present embodiment provides a combination drug composition of clobenil hydrochloride and azithromycin for the treatment of babesiosis, and the tested drug and drug dosage are shown in Table 1.

[0082] Table 1: Combination doses and administration time of the tested drugs

[0083]

[0084] The experimental results are as follows:

[0085] (1) The EIR changes of the medication group and the control group are shown in Table 2.

[0086] Table 2: Changes in EIR of the probenazol hydrochloride + azithromycin group and the control group

[0087]

[0088] (2) qPCR results

[0089] use 2 -△△ct The relative expression of the target gene in each sample was calculated by the method, and the change trend is as follows: figure 1 shown.

[0090] (3) Immunosuppressant resurgence test results

[0091] Table 3: EIR changes of each drug group and control group in the immunosuppressant experiment

[0092]

[0093] (4) The results of the second-generation mice resurgenc...

Embodiment 2

[0098] This example provides a combination of prohexidine hydrochloride and atovaquone for the treatment of babesiosis. Table 5 shows the tested drugs and drug doses.

[0099] Table 5: Combination dosage and administration time setting of the combination of prohexenidine hydrochloride and atovaquone

[0100]

[0101] The experimental results are as follows:

[0102] (1) The EIR changes of the medication group and the control group are shown in the table below

[0103] Table 6: Changes in EIR of the chlorhexidine hydrochloride + atovaquone treatment group and the control group

[0104]

[0105] (2) qPCR results

[0106] use 2 -△△ct The relative expression of the target gene in each sample was calculated by using the method, and the change trend is as follows: figure 2 shown. (3) The results of the immunosuppressant resurgence experiment

[0107] Table 7: Changes in EIR of each medication group and control group in the immunosuppressant experiment

[0108]

[01...

Embodiment 3

[0114] This example provides a combined medicinal composition of prohexidine hydrochloride and clindamycin for the treatment of babesiosis, and the tested drugs and their doses are shown in Table 9.

[0115] Table 9: Combination dosage and administration time setting of the combination of prohexidine hydrochloride and clindamycin

[0116]

[0117] The experimental results are as follows:

[0118] (1) The EIR changes of the medication group and the control group are shown in the table below

[0119] Table 10: Changes in EIR of prohexidine hydrochloride + clindamycin treatment group and control group

[0120]

[0121]

[0122] (1) qPCR results

[0123] use 2 -△△ct The relative expression of the target gene in each sample was calculated by using the method, and the change trend is as follows: image 3 shown.

[0124] (2) The results of the immunosuppressant resurgence experiment

[0125] Table 11: Changes in EIR of each medication group and control group in the imm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides robenidine hydrochloride, a drug combination thereof and application in treatment of babesiasis. The drug combination composition comprises a combination of robenidine hydrochloride and macrolide antibiotics, or a combination of robenidine hydrochloride and an antimalarial drug. The combination of robenidine hydrochloride and azithromycin, clindamycin or atorvaquone has a good treatment effect on babesiosis, has a better treatment effect compared with a clinically common combination of atorvaquone and azithromycin, and does not cause after-combustion and second-generation infection.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to prohexidine hydrochloride and its combined medicine and its application in treating babesiosis. Background technique [0002] Babesiosis is a contagious zoonotic parasitic disease caused by Babesia infection with a global distribution. The disease is transmitted by ticks or by blood transfusion. Babesia belongs to Protozoa, Apicomplexa, Sporozoasida, Piroplasmia, Piroplasmida, Babesia Babesia of the family (Babesiidae). At present, more than 100 species of Babesia that can infect mammals and birds have been identified, and Babesia that can infect humans mainly include Babesia vole (B.microti), Babesia divergens (B.divergens) Babesia (B. duncani), Orion Babesia (B. venatorum), etc. [0003] Babesia parasitizes in mammalian erythrocytes (including human erythrocytes), causing babesiosis. After a person is infected with Babesia, symptoms such as anemia, high fever, hemoglobinuri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/155A61K45/06A61K31/7056A61K31/7052A61K31/122A61P33/02
CPCA61K31/155A61K45/06A61K31/7056A61K31/7052A61K31/122A61P33/02A61K2300/00
Inventor 殷梦张皓冰陶奕霍乐乐姜斌魏玉芬
Owner 中国疾病预防控制中心寄生虫病预防控制所国家热带病研究中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap